GLPwatch

Anorectic state of obesity medications in the United States. Are leaner times ahead?

Expert Opin Pharmacother · 2020

Last updated 2026-05-28

Obesity affects 40% of people in the U.S., but prescription weight-loss medications are rarely used despite five options currently available. Several new medications are in late-stage clinical trials, but it remains uncertain whether these future treatments will fully address the country’s obesity healthcare needs.

AI summary of the abstract below.

JournalExpert Opin Pharmacother, 2020
Citations5
Relative citation ratio0.27
NIH percentile17
Molecules
Conditions studied Obesity

Abstract

: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known.: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

Verbatim abstract via PubMed 31762335 ↗